How large is the oncolytic virotherapy market?

In 2027 the market for oncolytic virotherapy is worth approximately USD 46.21 million.

How is the oncolytic virotherapy industry projected to perform over the next decade?

Oncolytic Virotherapy Market size was over USD 37.95 million in 2026 and is likely to grow at a 23.04% CAGR between 2027 and 2036, reaching USD 301.77 million by 2036.

How is the expansion of combination therapies with immunotherapy shaping adoption in the oncolytic virotherapy market?

Combination therapy development is broadening the clinical relevance of the oncolytic virotherapy market by integrating viral mechanisms with immunotherapy. This enhances therapeutic rationale, encourages partnerships, and supports wider clinical evaluation across tumors that respond inadequately to single-modality treatments.

Why is rising cancer burden accelerating investment in oncolytic virotherapy development programs?

Increasing cancer incidence is directing investment toward differentiated oncology platforms in the oncolytic virotherapy market. Developers and institutions are prioritizing gene-based and immune-activating therapies to address treatment-resistant tumors, supporting expanded clinical pipelines and research funding.

Why do Genetically Engineered Oncolytic viruses dominate the oncolytic virotherapy market?

Genetically Engineered Oncolytic viruses are the largest and fastest-growing segment because they offer optimized tumor selectivity, therapeutic payload delivery, and adaptable designs that support evolving oncology treatment strategies.

Why are Solid Tumors the fastest-growing application in the oncolytic virotherapy market?

Solid Tumors are expanding fastest as development programs broaden virotherapy use beyond traditional indications, creating greater commercial and clinical opportunities across larger patient populations.

What makes North America the leading region in the oncolytic virotherapy market?

North America leads because of its advanced oncology ecosystem, strong biopharmaceutical innovation, established clinical research infrastructure, and active cancer immunotherapy development.

Why is Asia Pacific emerging as the fastest-growing oncolytic virotherapy market?

Asia Pacific is projected to expand at a 28.16% CAGR, supported by rising oncology research, expanding healthcare capabilities, greater clinical development participation, and increasing adoption of advanced cancer therapies.

Who holds a significant market share in the oncolytic virotherapy landscape?

Major companies in the oncolytic virotherapy market include Amgen Inc. (United States), Takara Bio Inc. (Japan), Transgene SA (France), Shanghai Sunway Biotech Co., Ltd. (China), Pfizer Inc. (United States), Calidi Biotherapeutics, Inc. (United States), Lokon Pharma AB (Sweden), TILT Biotherapeutics Ltd. (Finland), CG Oncology, Inc. (United States).